前列腺癌组织中Hepsin的表达及其与临床病理特征的相关性研究

Correlation between Hepsin Expression and Clinicopathological Features of Prostate Cancer

目的研究Hepsin在前列腺癌和良性前列腺组织中的表达及其与前列腺癌各项临床病理特征的相关性。方法收集32例前列腺癌及15例良性前列腺组织标本,采用免疫组化SP法,比较两种组织中Hepsin表达的差异。结果32例前列腺癌组织中,Hepsin表达阳性率为93.8%,15例良性前列腺组织Hepsin表达阳性率为26.7%,两者比较,差异具有极显著性意义(P<0.01)。前列腺癌组织Hepsin表达与病理分级、肿瘤分期呈负相关关系(均P<0.01),与术前血清前列腺特异性抗原(PSA)水平无相关关系(P>0.05)。结论Hepsin在前列腺癌中过表达,并与肿瘤分级和分期相关,可用来评估前列腺癌的侵袭性,有望成为一种新的前列腺癌预后标记物。

Objective To investigate the expression of Hepsin in prostate cancer and benign prostate and its relationship with the clinicopathological features of prostate cancer. Methods By using immunohistochemical staining （SP method） techniques, the expression of Hepsin in 32 cases of prostate cancer and 15 cases of benign prostate was detected. The difference of expression between prostate cancer and benign prostate was compared. Results In 32 cases of prostate cancer specimens, 30 （93.8 %） had detectable hepsin. Four （26.7%） out of 15 cases of benign prostate specimens were positive for hepsin. There was statistically significant difference between tumor and benign prostate specimens （P〈0.01）. Hepsin expression was negatively correlated with histological grade and clinical stage （P〈0.01）, but not with preoperative serum prostate specific antigen level （P〉0.05）. Conclusion Hepsin was overexpressed in prostate cancer and had a positive relationship with histological grade and clinical stage. Hepsin may be used to assess the invasion of prostate cancer as a novel prognostic marker.